Fitzgerald Thomas A has filed 3 insider transactions across 1 company since May 2023.
Most recent transaction: a grant/award of 650000 shares of Transcode Therapeutics, Inc. ($RNAZ) on June 14, 2024.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 14, 2024 | Transcode Therapeutics, Inc. | $RNAZ | Fitzgerald Thomas A | Interim CEO, CFO | A | Stock Option (right to buy) | 650000 | $0.00 | 650,000.0000 | 155,831 | 9999.99% | 100.00% |
| Sept. 28, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Fitzgerald Thomas A | Chief Financial Officer | P | Common Stock | 49350 | $0.51 | 56,318.0000 | 30,494 | 708.24% | 100.00% |
| May 19, 2023 | Transcode Therapeutics, Inc. | $RNAZ | Fitzgerald Thomas A | Chief Financial Officer | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 18,593 | 9999.99% | 100.00% |